Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: EyePoint, Inc.

Market Cap 1.14B 993M 919M 861M 1.61B 107B 1.62B 10.91B 4.23B 52.88B 4.27B 4.18B 184B P/E 2026 *
-3.85x
P/E 2027 * -4.96x
Enterprise Value 844M 736M 682M 638M 1.2B 79.66B 1.2B 8.09B 3.13B 39.21B 3.17B 3.1B 136B EV / Sales 2026 *
495x
EV / Sales 2027 * 17.5x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+3.27%
1 week+8.64%
1 month+16.07%
3 months-0.44%
6 months-20.40%
Current year-25.67%
1 week 11.93
Extreme 11.93
14.03
1 month 11.3
Extreme 11.295
14.03
Current year 11.3
Extreme 11.295
18.87
1 year 7.94
Extreme 7.94
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 68 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 68 10/07/2023
Director/Board Member 80 03/09/2024
Director/Board Member 58 15/07/2019
Date Insider Type Main position Quantity % Market Cap.
05-25Fiscal year

Chief Financial Officer

18,627 0.0222%
04-17Fiscal year

Chief Technology Officer

7,311 0.0088%
03-23Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+3.27%+8.64%+52.24%+107.65% 1.14B
-1.21%-5.37%+39.94%+145.38% 980B
-2.48%-4.17%+51.52%+39.07% 550B
-2.14%-3.68%+16.71%+56.15% 382B
-1.75%+0.25%+25.86%+16.53% 317B
+0.61%-2.53%+25.46%+12.27% 270B
+0.22%-2.67%+24.57%+30.34% 269B
+4.59%+3.68%-39.28%-46.92% 191B
-1.19%-4.65%+16.56%+47.00% 182B
-1.35%-1.68%+14.59%+56.94% 154B
Average -0.12%-1.75%+22.82%+46.44% 329.52B
Weighted average by Cap. -0.97%-3.37%+28.33%+63.90%

Financials

2026 *2027 *
Net sales 1.71M 1.49M 1.38M 1.29M 2.42M 161M 2.43M 16.35M 6.34M 79.28M 6.41M 6.27M 275M 51.01M 44.47M 41.19M 38.56M 72.31M 4.81B 72.75M 489M 189M 2.37B 191M 187M 8.23B
Net income -311M -271M -251M -235M -441M -29.36B -444M -2.98B -1.16B -14.45B -1.17B -1.14B -50.18B -262M -229M -212M -198M -372M -24.77B -374M -2.51B -975M -12.19B -985M -964M -42.33B
Net Debt -294M -257M -238M -223M -417M -27.77B -420M -2.82B -1.09B -13.67B -1.1B -1.08B -47.47B -248M -216M -200M -188M -352M -23.42B -354M -2.38B -922M -11.53B -932M -912M -40.04B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
18/06/26 13.58 $ +3.27% 1,290,270
17/06/26 13.15 $ +2.10% 1,180,462
16/06/26 12.88 $ +6.62% 1,471,638
15/06/26 12.08 $ -7.29% 1,084,002
12/06/26 13.03 $ +4.24% 1,093,547
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.58USD
Average target price
37.00USD
Spread / Average Target
+172.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!